Cargando…
CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma
BACKGROUND: Patients suffering from squamous cell carcinoma of the larynx (LSCC) with lymphatic metastasis have a relatively poor prognosis and often require radical therapeutic management. The mechanisms which drive metastasis to the lymph nodes are largely unknown but may be promoted by a pro-angi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845191/ https://www.ncbi.nlm.nih.gov/pubmed/29523110 http://dx.doi.org/10.1186/s12885-018-4180-5 |
_version_ | 1783305376246005760 |
---|---|
author | Schlüter, Anke Weller, Patrick Kanaan, Oliver Nel, Ivonne Heusgen, Lukas Höing, Benedikt Haßkamp, Pia Zander, Sebastian Mandapathil, Magis Dominas, Nina Arnolds, Judith Stuck, Boris A. Lang, Stephan Bankfalvi, Agnes Brandau, Sven |
author_facet | Schlüter, Anke Weller, Patrick Kanaan, Oliver Nel, Ivonne Heusgen, Lukas Höing, Benedikt Haßkamp, Pia Zander, Sebastian Mandapathil, Magis Dominas, Nina Arnolds, Judith Stuck, Boris A. Lang, Stephan Bankfalvi, Agnes Brandau, Sven |
author_sort | Schlüter, Anke |
collection | PubMed |
description | BACKGROUND: Patients suffering from squamous cell carcinoma of the larynx (LSCC) with lymphatic metastasis have a relatively poor prognosis and often require radical therapeutic management. The mechanisms which drive metastasis to the lymph nodes are largely unknown but may be promoted by a pro-angiogenic tumor microenvironment. In this study, we examined whether the number of microvessels and the expression level of vascular endothelial growth factor (VEGF) in the primary tumor are correlated with the degree of lymph node metastasis (N-stage), tumor staging (T) and survival time in LSCC patients. METHODS: Tissue-Microarrays of 97 LSCC patients were analyzed using immunohistochemistry. The expression of VEGF was scored as intensity of staining (low vs high) and the number of CD31-positive vessels (median </≥7 vessels per visual field) was counted manually. Scores were correlated with N-stage, T-stage and 5-year overall survival rate. RESULTS: A high expression of angiogenic biomarkers was not associated with poor overall survival in the overall cohort of patients. Instead high CD31 count was associated with early stage cancer (p = 0.004) and in this subgroup high VEGF expression correlated with poor survival (p = 0.032). Additionally, in early stage cancer a high vessel count was associated with an increased recurrence rate (p = 0.004). CONCLUSION: Only in the early stage subgroup a high expression of angiogenic biomarkers was associated with reduced survival and an increased rate of recurrence. Thus, biomarkers of angiogenesis may be useful to identify high risk patients specifically in early stage LSCC. |
format | Online Article Text |
id | pubmed-5845191 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58451912018-03-14 CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma Schlüter, Anke Weller, Patrick Kanaan, Oliver Nel, Ivonne Heusgen, Lukas Höing, Benedikt Haßkamp, Pia Zander, Sebastian Mandapathil, Magis Dominas, Nina Arnolds, Judith Stuck, Boris A. Lang, Stephan Bankfalvi, Agnes Brandau, Sven BMC Cancer Research Article BACKGROUND: Patients suffering from squamous cell carcinoma of the larynx (LSCC) with lymphatic metastasis have a relatively poor prognosis and often require radical therapeutic management. The mechanisms which drive metastasis to the lymph nodes are largely unknown but may be promoted by a pro-angiogenic tumor microenvironment. In this study, we examined whether the number of microvessels and the expression level of vascular endothelial growth factor (VEGF) in the primary tumor are correlated with the degree of lymph node metastasis (N-stage), tumor staging (T) and survival time in LSCC patients. METHODS: Tissue-Microarrays of 97 LSCC patients were analyzed using immunohistochemistry. The expression of VEGF was scored as intensity of staining (low vs high) and the number of CD31-positive vessels (median </≥7 vessels per visual field) was counted manually. Scores were correlated with N-stage, T-stage and 5-year overall survival rate. RESULTS: A high expression of angiogenic biomarkers was not associated with poor overall survival in the overall cohort of patients. Instead high CD31 count was associated with early stage cancer (p = 0.004) and in this subgroup high VEGF expression correlated with poor survival (p = 0.032). Additionally, in early stage cancer a high vessel count was associated with an increased recurrence rate (p = 0.004). CONCLUSION: Only in the early stage subgroup a high expression of angiogenic biomarkers was associated with reduced survival and an increased rate of recurrence. Thus, biomarkers of angiogenesis may be useful to identify high risk patients specifically in early stage LSCC. BioMed Central 2018-03-09 /pmc/articles/PMC5845191/ /pubmed/29523110 http://dx.doi.org/10.1186/s12885-018-4180-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Schlüter, Anke Weller, Patrick Kanaan, Oliver Nel, Ivonne Heusgen, Lukas Höing, Benedikt Haßkamp, Pia Zander, Sebastian Mandapathil, Magis Dominas, Nina Arnolds, Judith Stuck, Boris A. Lang, Stephan Bankfalvi, Agnes Brandau, Sven CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma |
title | CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma |
title_full | CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma |
title_fullStr | CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma |
title_full_unstemmed | CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma |
title_short | CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma |
title_sort | cd31 and vegf are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845191/ https://www.ncbi.nlm.nih.gov/pubmed/29523110 http://dx.doi.org/10.1186/s12885-018-4180-5 |
work_keys_str_mv | AT schluteranke cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT wellerpatrick cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT kanaanoliver cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT nelivonne cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT heusgenlukas cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT hoingbenedikt cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT haßkamppia cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT zandersebastian cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT mandapathilmagis cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT dominasnina cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT arnoldsjudith cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT stuckborisa cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT langstephan cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT bankfalviagnes cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma AT brandausven cd31andvegfareprognosticbiomarkersinearlystagebutnotinlatestagelaryngealsquamouscellcarcinoma |